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Abstract
Background: Neuroscientists often need to access a wide range of data sets distributed over the Internet. These data
sets, however, are typically neither integrated nor interoperable, resulting in a barrier to answering complex
neuroscience research questions. Domain ontologies can enable the querying heterogeneous data sets, but they are not
sufficient for neuroscience since the data of interest commonly span multiple research domains. To this end, e-
Neuroscience seeks to provide an integrated platform for neuroscientists to discover new knowledge through seamless
integration of the very diverse types of neuroscience data. Here we present a Semantic Web approach to building this
e-Neuroscience framework by using the Resource Description Framework (RDF) and its vocabulary description
language, RDF Schema (RDFS), as a standard data model to facilitate both representation and integration of the data.
Results: We have constructed a pilot ontology for BrainPharm (a subset of SenseLab) using RDFS and then converted
a subset of the BrainPharm data into RDF according to the ontological structure. We have also integrated the converted
BrainPharm data with existing RDF hypothesis and publication data from a pilot version of SWAN (Semantic Web
Applications in Neuromedicine). Our implementation uses the RDF Data Model in Oracle Database 10g release 2 for
data integration, query, and inference, while our Web interface allows users to query the data and retrieve the results
in a convenient fashion.
Conclusion:  Accessing and integrating biomedical data which cuts across multiple disciplines will be increasingly
indispensable and beneficial to neuroscience researchers. The Semantic Web approach we undertook has demonstrated
a promising way to semantically integrate data sets created independently. It also shows how advanced queries and
inferences can be performed over the integrated data, which are hard to achieve using traditional data integration
approaches. Our pilot results suggest that our Semantic Web approach is suitable for realizing e-Neuroscience and
generic enough to be applied in other biomedical fields.
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Background
e-Science involves developing tools, technologies, and
infrastructure to support multidisciplinary and collabora-
tive science enabled by the Internet [1]. One of the chal-
lenges that e-Science aims to address is data integration. e-
Neuroscience [2], otherwise known as neuroinformatics,
shares the same vision as e-Science but focuses on the neu-
rosciences. It is also encompassed by the informatics-ori-
ented goal of the Human Brain Project, which emphasizes
the importance of integrating heterogeneous neuro-
science-related information from the molecular level to
the behavioral level [3]. Integrating neuroscience data,
including sequence data, molecular data, disease data and
behavioral data, will be a significant step towards better
understanding brain function [4].
By combining the experimental results produced by
multi-disciplinary groups, one can allow a more thorough
investigation and understanding of complex neuroscience
research problems, including the study of neurodegenera-
tive diseases such as Alzheimer's Disease (AD) and Parkin-
son's Disease (PD) [2]. Below, we discuss some of the
challenges involved in integrating rapidly growing hetero-
geneous and distributed neuroscience data.
1.  Registry. A large number of neuroscience resources
have been developed independently to address various
research needs. While search engines (e.g., Google) can
help users locate neuroscience resources of interest, such
keyword based search approaches suffers from the prob-
lem of specificity and sensitivity. For example, if a search
is performed using the keyword "neuron", a large number
of hits will be returned. To address this problem, central
registries of neuroscience resources have been created to
categorize and keep track of existing neuroscience data
sets. These registries provide search interfaces for users to
find data of potential interest. The Neuroscience Database
Gateway (NDG) [5] is one such example. NDG was
launched in 2004 as a pilot project sponsored by the Soci-
ety for Neuroscience, with an exclusive focus on categoriz-
ing neuroscience resources. It employs a set of standard
terms (e.g., name, description, URL, and species) for
describing each resource (e.g., a database or a software
tool). As the number of neuroscience resources continues
to grow, such a centralized approach to registering
resources may not be easily maintainable (it is difficult for
a single person or a single group to keep track of such a
rapidly growing collection of resources). A better and
more efficient framework that allows registration and dis-
covery of this kind of distributed resource will be neces-
sary.
2.  Interface. Within NDG each of the different data
sources has its own data format and interface. For exam-
ple, Cell-Centered Database (CCDB) [6] (cellular imaging
data) provides a free text search interface; SenseLab [7]
(integration of multidisciplinary sensory data) has a struc-
tured form search interface; and CoCoDat [5] (cortical cell
and micro-circuitry data) is available for download as a
Microsoft Access database. Examples of the differing Web
interfaces are shown in Figure 1. Although each of these
data sources contains different types of data, they refer to
common bio-entities. Such heterogeneity in data format
and user interface makes data interoperability and data
analysis difficult, yet currently the only way to integrate
the data is to do it manually. A standardized and machine-
understandable data format with an open and unified
data access model is crucial to building a data integration
framework for e-Neuroscience.
3. Nomenclature. One of the difficulties in enabling neu-
roscience data sources to be broadly sharable is a lack of
standard nomenclature. For example, different terms (e.g.,
Neural Arch and Vertebral Arch) may be used to describe
the same neuro-anatomical region (e.g., part of the spinal
cord). Ambiguity also arises when the same term is asso-
ciated with multiple meanings (e.g., spine could mean
vertebral spine or dendritic spine). It would be highly
advantageous if there were an e-Neuroscience framework
that could better reconcile the ambiguities.
4. Granularity. Different neuroscience data sources may
model the same type of data at different levels of granular-
ity. For example, CCDB uses a single "dendrite" compart-
ment for all data associated with dendrites, whereas
NeuronDB (a subdatabase of SenseLab) subdivides den-
drites into types (e.g., apical and basal) and compart-
ments (e.g., proximal, medial, and distal). As a result, data
within NeuronDB can be associated with specific den-
dritic compartments, which is not possible in CCDB. An
ideal data framework would be able to model data at dif-
fering levels of granularity.
Semantic Web approach to representing and integrating 
data
The primary goal of the Semantic Web is to expose the
semantics of Web-accessible data using a machine-reada-
ble knowledge representation format so that data can be
more easily interpreted and integrated by computer pro-
grams (or Web agents). As a result, the Semantic Web con-
sists of components that aim to fulfill the requirements in
this realm. The fundamental components of the Semantic
Web include the following: knowledge representation,
ontological languages, and Semantic-Web-aware tools.
Knowledge representation
Knowledge representation comes in different forms that
exhibit different levels of complexity. A controlled vocab-
ulary is a knowledge base that holds definitions of terms.
A thesaurus is a more expressive knowledge base that, inBMC Bioinformatics 2007, 8(Suppl 3):S4 http://www.biomedcentral.com/1471-2105/8/S3/S4
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addition, holds assertions regarding the semantic rela-
tionships between the terms. An ontology is a specifica-
tion of a representational vocabulary for a shared domain
of discourse [8]. It captures domain concepts and their
relations and properties. Ontologies can be categorized
into upper level ontology (contains common and generic
knowledge that can be shared across different domains),
middle level ontology (contains focused domain span-
ning knowledge), and domain level ontology (contains
domain-specific knowledge) [9]. With the application of
the Semantic Web, controlled vocabularies, thesauri, and
ontologies are exposed to processing by Web-aware
agents, as well as to human access and interpretation. This
facilitates extensible knowledge representation and
semantic interoperability, and critically deepens our abil-
ity to treat the Web as a true knowledge base.
Recognizing the increasing need for using expressive bio-
ontologies to facilitate machine-based data integration
and inference, community efforts have begun to build
ontologies for use by computer applications deployed in
different domains of biosciences. Examples include the
Gene Ontology [10] (a controlled vocabulary describing
gene and gene product attributes), Plant Ontology [11] (a
controlled vocabulary describing plant structures, growth,
and developmental stages), and Unified Medical Lan-
guage System [12] (a vocabulary database about biomed-
ical and health related concepts). In response to the
growing number of bio-ontologies, the National Center
for Biomedical Ontologies (NCBO) [13] was established
to enable researchers to find, create, disseminate, and
manage biomedical information and knowledge in a
machine-processable form. The Center's resources include
the Open Biomedical Ontologies library [14], the Open
Biomedical Data (OBD) repositories, and tools for access-
ing and using these biomedical ontologies and their asso-
ciated data in research. Many of the ontologies hosted by
the NCBO can be cross-referenced or inter-linked to facil-
Examples of three neuroscience database Web interfaces Figure 1
Examples of three neuroscience database Web interfaces. The Web interfaces of CocoDat, NeuronDB, and the Cell 
Centered Database.BMC Bioinformatics 2007, 8(Suppl 3):S4 http://www.biomedcentral.com/1471-2105/8/S3/S4
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itate more comprehensive knowledge acquisition,
although much research is still in progress to help deter-
mine equivalence across ontologies, and to further
explore automating the labor intensive mapping process.
There are also ongoing efforts to create upper level ontol-
ogies for disparate domains. This kind of ontology focuses
on providing a set of general concepts upon which
domain-specific ontologies (e.g., microarrays, proteom-
ics, and pathways) could be constructed. Examples in the
biological domain include the Functional Genomics
Investigation Ontology (FuGO) [15], and Ontology of
EXPeriment (EXPO) [16].
In research investigations that commonly span domains,
such as neuroscience, providing the ability to construct
upper ontologies and bridge ontologies is critical to inter-
operability.
Semantic Web languages
To enable computers to process, understand, and infer-
ence over an ontology, it is necessary to have a computer
language, or what we call an ontological language, to for-
malize an ontology in a way that it can be reasoned over
by software automatically. It is also essential to have a
common format that can facilitate the interchange of data.
To this end, the W3C has recommended two standards for
building an ontology in the Semantic Web – Resource
Description Framework (RDF) [17] and Web Ontology
Language (OWL) [18].
RDF models concepts and their instances in a format
called a triple. A triple is an RDF statement which contains
a subject, a predicate and an object about a resource where
the subject is the resource itself, the predicate is the rela-
tionship between the resource and the object, and the
object can be another resource or a data value. RDF in fact
can be specified in different syntax formats, although the
most commonly used format is the RDF/XML, which
employs the eXtensible Markup Language (XML) to struc-
ture its representation of resources. Descriptions of the
concepts and their relations (e.g., subclass/superclass) are
specified separately in a specialized RDF format called
RDF Schema (RDFS) [19]. The following example illus-
trates an RDF statement:
<http://en.wikipedia.org/wiki/Dopamine#,
http://en.wikipedia.org/wiki/Function#,
http://en.wikipedia.org/wiki/Neurotransmitter#>
expressing that Dopamine has the Function of being a Neu-
rotransmitter. Each component of the triple is identified
using a Uniform Resource Identifier (URI) [20]. When
resources have the same URI they are assumed to be the
same entity, and any data about the entity can be merged.
As triple statements become connected together, they
form a directed labeled graph.
OWL extends RDF by adding more vocabulary to describe
the relations such as cardinality and equality among
classes and properties. Advanced knowledge representa-
tion includes making assertions or claims about explicit
objects (e.g., "acetylcholinesterase is an enzyme"). Repre-
senting knowledge in such an explicit form in OWL is
based on Description Logics, which enables computers to
draw new conclusions from existing knowledge. Insights
from the Description Logics research community have
had a strong influence on the design of OWL, particularly
on the formalization of the semantics, the choice of lan-
guage constructors, and the integration of data types and
data values [21].
We have chosen to use RDFS for knowledge representa-
tion in the initial stages of this project, as it is well devel-
oped, widely used, and expressive enough for our case.
Semantic Web-aware tools
Ontologies (written in RDFS or OWL) are the key compo-
nents of the Semantic Web. Without suitable tools for
developing, processing, storeing, and inferencing over the
data, it would not be possible to infer new knowledge
could hardly be inferred. Consequently, a large number of
open source and commercial Semantic Web tools have
been developed. They are:
1. Ontology editors and visualization tools. These tools
allow users to develop, edit, and visualize ontologies and
their associated data. Examples include Protégé [22],
WebOnto [23], and GrOWL [24]. There are also advanced
ontology editors that allow alignment and integration of
multiple ontologies (e.g., COBrA [25]).
2. Parsers. To enable the development of computer appli-
cations that utilize and process ontologies, RDF and OWL
parsers have been made available for most popular pro-
gramming languages. For example, PerlRDF is one of the
RDF parsers written in Perl [26]. Jena is a framework for
building Semantic Web applications and for parsing RDF,
RDFS and OWL in the Java programming environment
[27].
3. Database and querying tools. To provide persistence,
management and querying capabilities for RDF/OWL,
several RDF database systems have been implemented.
Among them, Sesame (a.k.a OpenRDF) [28] and Kowari
[29] are open-source RDF database systems while the Ora-
cle RDF Data Model [30] is a feature of the Oracle Data-
base and therefore a commercial offering. Some of these
database systems (e.g., Sesame) implement their RDFBMC Bioinformatics 2007, 8(Suppl 3):S4 http://www.biomedcentral.com/1471-2105/8/S3/S4
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query languages in compliance with the SPARQL standard
specifications [31]. Besides, tools such as D2RQ [32] are
also available for mapping relational schema to OWL/
RDFS ontologies.
4. Reasoners. To support reasoning based on Description
Logics specified in OWL, a number of reasoners have been
developed including Racer [33], FaCT [34], and Pellet
[35].
Results
As described in the Methods section, we hand-crafted an
ontology for BrainPharm using RDFS. We then instanti-
ated the ontology with some pilot data, which our neuro-
scientists extracted from a subset of the BrainPharm data.
Figure 2 shows a portion of the pilot data set (pathological
mechanisms) in tabular format. The first four columns
contain information about different types of neurons
including their neuronal properties, such as receptors and
channels localized to different neuronal compartments.
The remaining columns capture information about (i) the
pathological changes caused by certain pathological
agents (e.g., beta Amyloid) to the neuronal properties
(e.g., beta Amyloid inhibits the I Calcium channel of CA1
pyramidal neuron), (ii) the drugs and their actions on the
pathological changes (e.g., Nifedipine reduces the patho-
logical effect of beta Amlyloid on the molecular properties
of CA1 pyramidal neuron), (iii) stages of the disease (e.g.,
early, middle, and late stages), and (iv) literature sources
(e.g., PubMed sources).
We loaded a subset of BrainPharm in RDF, and a subset of
SWAN in RDF, into the ORACLE RDF Data Model.  We
then created inference rules based upon the RDFs. In our
pilot use case, we loaded: (i) the BrainPharm drug-related
data including the drug property and drug action informa-
tion related to the pathological mechanisms underlying
AD, and (ii) the SWAN data including publication,
hypothesis, and annotation information [36]. This
approach is potentially easier to manage and adapt than
integrating many data sets using a relational model, as no
schema has to be pre-defined for our RDF models.
As a demonstration, we developed a Web-based applica-
tion called "AlzPharm" [37] which allows users to relate
the drug information from BrainPharm to the publication
information stored in SWAN. Our Web interface uses Java
server faces to render different information into different
User Interface (UI) components, and the connection to
the Oracle database is made available by Java Database
Connectivity (JDBC).
Figure 3 shows some of the UI components of our demo
and depicts a schematic data flow of the information
transferring from their original data sources to the Oracle
RDF Data Models. Figure 3A shows that the data originat-
ing from BrainPharm are loaded into our database
Partial BrainPharm data Figure 2
Partial BrainPharm data. A portion of the pilot data set retrieved from the BrainPharm database.BMC Bioinformatics 2007, 8(Suppl 3):S4 http://www.biomedcentral.com/1471-2105/8/S3/S4
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directly after RDF conversion, and that the data originat-
ing from AlzForum [38] are converted into RDF, made
available by SWAN at their website, and then loaded into
our database. Figure 3B shows the original Web interface
to the AlzForum data repository, which is not in RDF for-
mat. Figure 3C shows part of the Web query interface that
we developed to allow users to query data across both the
BrainPharm and SWAN datasets.
An integrated query
Our Web interface provides not only information about
the individual datasets in our database, but also a simple
text field for scientists to enter a drug name for finding the
publications in SWAN that mention the molecular targets
of interest. The drug being searched has to exist in the
BrainPharm dataset, otherwise there will be no result. For
this reason, we also provide drug name suggestions, ena-
bled by the Asynchronous JavaScript and XML (AJAX)
technology, to the users based the data in real time. After
our system receives the search request from the user, it
executes the following SQL query statement and queries
the underlying RDF models with the specified drug name:
SELECT distinct drugname DRUG_NAME, target TARGET,
journal JOURNAL, title TITLE, pmid PMID
FROM TABLE(
SDO_RDF_MATCH(
'(?drug b:name ?drugname)
(?drug b:hasMolecularTarget ?target)
(?mech b:hasPharmacologicalAgent ?drug)
(?mech b:hasPharmacologicalTarget ?path)
(?path b:hasPathology ?disease)
(?disease b:name ?disname)'
,
SDO_RDF_Models('brainpharm'),
SDO_RDF_Rulebases('RDFS'),
SDO_RDF_Aliases(SDO_RDF_Alias('b','http://
ycmi.med.yale.edu/brainpharm#')),
'lower(disname) = "alzheimer""s disease"'
)
) bpharm,
TABLE(
SDO_RDF_MATCH(
'(?pub s:title ?title)
(?pub s:journal ?journal)
(?pub s:abstract ?abs)
(?pub s:pmid ?pmid)
(?pub rdf:type s:Publication)'
,
SDO_RDF_Models('swan'),
SDO_RDF_Rulebases('RDFS'),
SDO_RDF_Aliases(SDO_RDF_Alias('s','http://purl.org/
swan/)),
null
)
) swan
where regexp_like(swan.abs, bpharm.target, 'i') and
lower(drugname) = lower(?)
The query results shown in Figure 3C list the SWAN pub-
lications related to the drug Donepezil (with acetylcho-
linesterase being the molecular target of the drug), which
is indication by "?" at the end of the query. The user can
click on the drug name to get more detailed information
directly from BrainPharm about the effect of the drug on
some known pathological mechanism(s) related to AD. In
addition, users can also click on the AlzForum link under
the PMID (PubMed ID) column to go to AlzForum for
additional comments that have been given by AD
researchers for that publication, as shown in Figure 3B.
The results demonstrated how a complex query can be for-
mulated to integrate BrainPharm's drug data and SWAN's
publication data. In addition, it also demonstrated the use
of RDF inferencing based on the parent-child (is-a) rela-
tionship between the Publication class (e.g., original arti-
cles retrieved from PubMed) and ARFPublication  class
(e.g., PubMed articles that have been commented by
researchers/curators associated with AlzForum) as defined
in the SWAN RDF Schema and shown below.BMC Bioinformatics 2007, 8(Suppl 3):S4 http://www.biomedcentral.com/1471-2105/8/S3/S4
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The AlzPharm Web application Figure 3
The AlzPharm Web application. (A) The data sources of the application. (B) The AlzForum website. (C) The interface of 
the application.BMC Bioinformatics 2007, 8(Suppl 3):S4 http://www.biomedcentral.com/1471-2105/8/S3/S4
Page 8 of 12
(page number not for citation purposes)
<rdf:Description rdf:about="ARFPublication">
<rdfs:label>ARFPublication</rdfs:label>
<rdf:type rdf:resource="Class"/>
<rdfs:subClassOf rdf:resource="Publication"/>
</rdf:Description>
Since our query has specified retrieval of all the related
Publications (?pub rdf:type s:Publication) from the data-
set, the Oracle RDF Data Model will identify all the publi-
cations – including the ARF publications, which are
related to AD drugs (e.g., Donepezil) based on the RDFS
rules that contain their relationship we defined. Although
the hierarchical relation here only has two levels, the is-a
inference could be applied to any number of levels.
Semantic inferencing is not directly supported by the rela-
tional approach.
A "group-by" query
As shown in Figure 3C (bottom), we queried BrainPharm
to group and count AD drugs based on their molecular
targets and clinical usage. The SQL query statement is as
follows:
SELECT count(distinct bpharm.drugname)
NO_OF_DRUGS,
bpharm.target MOLECULAR_TARGET,
bpharm.disname CLINICAL_USAGE
FROM TABLE(
SDO_RDF_MATCH(
'(?drug b:hasMolecularTarget ?target)
(?mech b:hasPharmacologicalAgent ?drug)
(?mech b:hasPharmacologicalTarget ?path)
(?path b:hasPathology ?disease)
(?drug b:name ?drugname)
(?disease b:name ?disname)'
,
SDO_RDF_Models('brainpharm'),
SDO_RDF_Rulebases('RDFS'),
SDO_RDF_Aliases(SDO_RDF_Alias('b','http:ontowed.y
ale.edu/AlzPharm/download/brainp harm.rdfs')),
'lower(disname) = "alzheimer""s disease"'
)
) bpharm
group by bpharm.target, bpharm.disname
The output of this query indicates that there are two
groups of drugs available for AD. The first one contains
one drug, which molecular target is acetylcholinesterase.
The second group also contains one drug but its molecular
target is calcium ion channel. The query demonstrated
how to make use of the "GROUP BY" feature (which is
supported by standard SQL) to perform aggregation on
RDF data. Implementations of other RDF query languages
by other RDF databases do not support aggregate func-
tions such as "COUNT", "SUM" and "AVERAGE" with
"GROUP BY". The Oracle Database has the advantage of
the RDF query being embedded within a SQL statement.
Conclusions and future directions
As Sir Tim Berners-Lee has reinforced, today most of the
world's data are still locked in large data stores and are not
published as an open Web of inter-referring resources
[39]. Areas such as neuroscience, which rely heavily on
analyzing a tremendous amount of data of disparate and
diverse types, cannot fully leverage the potential of the
available knowledge that is captured in this way. There is
an emerging need for an infrastructure that can facilitate
the interchange of such data. In this paper, we have shown
the benefits of exposing data in RDF format, which can be
shared, integrated, and reasoned about. We have also
shown how to use the Oracle RDF Data Model to create a
Semantic Web repository for integrating data relating to
AD from BrainPharm and SWAN. We further demon-
strated the RDF querying and RDFS inferencing features,
including the support of data aggregation functions
(based on traditional SQL) and semantic inference rules
(based on RDFS) provided by the Oracle RDF Data Model,
which can hardly be achieved by traditional data integra-
tion. The Oracle Database's extensions to SQL for query-
ing RDF data are particularly powerful – allowing
relational data to be queried alongside RDF data. For
example, one can formulate a complex nested query that
retrieves data from both an RDF graph and a relational
table and join the query results using a relational join.
Technically, our approach can also be adapted to other
integration solutions such as data warehousing and query
mediation.BMC Bioinformatics 2007, 8(Suppl 3):S4 http://www.biomedcentral.com/1471-2105/8/S3/S4
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While neuroscientists always need to access and integrate
biomedical data that span multiple disciplines, integrat-
ing neuroscience data using our proposed Semantic Web
approach appears to be effective, based on our results. We
believe that our approach is the robust candidate for e-
Neuroscience and could be generalizable to be applied in
other biomedical fields.
To increase the use of Semantic Web in e-Neuroscience,
we suggest the following future work:
1. User-friendly query interface. We will extend the Web-
based application to allow users to perform more kinds of
queries (e.g., queries that are based on drug properties and
neuronal properties).
2. Enhanced integration. To support better integrative
neuroscience research, we will strengthen the linkage
between BrainPharm and SWAN. While we are in the
process of enhancing the ontological representation of
BrainPharm and SWAN, more AD-related data are being
added to the two databases.
3. OWL support. Oracle Database 10g release 2 provides
support for storing, querying, and inferencing over RDF
and RDFS. Currently, it is also possible to store OWL in
the Oracle RDF Data Model, but OWL inferencing can
only be performed indirectly through application layer
functionality. The next release of the Oracle Database will
provide native support for OWL and we plan to take
advantage of this capability to better integrating disparate
data sources and ensure more advanced inferencing.
4. Query mediation. The data integration system we dem-
onstrated focuses on building a central repository of data.
We are interested in exploring a federated data approach,
where the query is mediated across distributed data
sources. Efforts in this area are ongoing within the compu-
ter science research community (e.g., [40]). Initial work
has started within the life science domain, e.g., Stephens
et al. have described a federated database approach for
querying drug safety data [41].
5. Use case. To make Semantic Web technologies useful to
neuroscience researchers, it is important to drive our
Semantic Web development by real use cases. While
SenseLab focuses on data at the molecular and basic
research level, AlzForum focuses on cataloging and docu-
menting research hypotheses (including clinical trial stud-
ies) relating to AD. The potential benefit of integrating
SenseLab and AlzForum is to support translational
research in AD. We will develop use cases in this transla-
tional research context. For this, we will need to interact
closely with domain experts.
Methods
We used the Oracle RDF Data Model provided by Oracle
Database10 g release 2 to store and semantically integrate
data from two independently created neuroscience data
sources, namely, BrainPharm (a subset of SenseLab [7])
and SWAN [36]:
Data sources
BrainPharm
BrainPharm includes data for support of research on
drugs for the treatment of neurological disorders [42]. It
contains information about the effect of drugs on patho-
logical (or molecular) mechanisms (which involve neuro-
nal properties such as receptors, currents, and
neurotransmitters) mediating the pathological changes in
various neurological disorders such as AD. Figure 4 shows
the ontology diagram of BrainPharm, which was created
manually using Protégé. As shown in the diagram, the
main classes include: disease (e.g., AD), drug (subclass of
agent),  pathological mechanism (which contains related
pharmacological and pathological information), patholog-
ical change (which has a pathological agent and its effect and
targets), neuron (e.g., CA1 pyramidal neuron), and neuron
property (which has the following subclasses: transmitter,
current, and receptor). There are also non-hierarchical rela-
tionships among these classes. For example, pathological
mechanism relates to drug through the hasPharmacologica-
lAgent property. The BrainPharm ontology was designed
and populated based on the input from our neuroscien-
tists.
SWAN/AlzForum
SWAN is a project to develop knowledge management
tools and resources for AD researchers, based on an eco-
system model of scientific discourse [43]. The SWAN
project is currently developing an OWL ontology for rep-
resenting information about scientists, experiments, pub-
lications, scientific data, bibliographic data, scientific
ontologies, biomedical research collaborations, and sci-
entific Web communities. A beta release of SWAN is now
under development, with planned deployment on the
Alzheimer Research Forum Web site [44] in early to mid
2007. AlzForum [38] is a widely used scientific Web com-
munity, which reports on the latest Alzheimer's scientific
research, and develops data sources of genes, scientific
articles, animal models, antibodies, medications, grants,
research jobs, and more. Prior to employing OWL to
implement the Semantic Web, a SWAN pilot version was
implemented in 2005–2006 using RDF/S to represent the
data (we acquired in this project). Figure 5 shows the
ontology diagram of a portion of the SWAN pilot knowl-
edgebase.BMC Bioinformatics 2007, 8(Suppl 3):S4 http://www.biomedcentral.com/1471-2105/8/S3/S4
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Data conversion and storing
As a pilot demonstration, we have integrated the drug-
related information extracted from BrainPharm that is
related to AD with the SWAN hypothesis and publication
information extracted from SWAN/AlzForum. We have
manually created the RDFS for BrainPharm as described
before and converted the extracted data into RDF. Since
the SWAN data are already available in RDF format, we
then loaded both the BrainPharm and SWAN data,
including their corresponding RDFS, into the Oracle RDF
Data Model using its data loader tool, which supports
loading RDF in N-triple format. As a result, we used Jena
to simply convert the RDF/XML into N-triple before we
loaded the data. While SWAN already has its own name-
space for URIs, we defined our BrainPharm namespace for
URIs so that data values referenced by different URI's
could be differentiated and joined correctly.
RDF queries
We used the SPARQL-like RDF query syntax required by
the Oracle RDF Data Model to query our data in RDF.
Examples of such kind of queries are illustrated in the
results section.
Web application
Our Web application has been implemented using the
Java Web technology. We have also used AJAX on the Web
page to perform asynchronous query to the server so as to
provide some non-critical information, such as drug name
suggestion in the search, in a timely and non-interruptive
manner. Moreover, we have used Java Server Faces to
render different information, such as drug count and
search result, into different UI components on the inter-
face. Our application has been deployed to a Tomcat Web
Application Server 5.5 running on a SUSE Linux machine
with four Intel Xeon CPUs at 2.80 GHz and 4 GB memory,
which is where the Oracle Database is also running.
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